BESREMi® is approved as first-line monotherapy in adults for the treatment of Polycythaemia vera (PV) without symptomatic splenomegaly BESREMi® showed high and durable hematologic response, molecular response and disease...

weiter zu "AOP Orphan announces EU Marketing Authorization for BESREMi® (Ropeginterferon alfa-2b) for rare blood cancer (PV) "

AOP Orphan Pharmaceuticals AG (AOP Orphan) and Chord Therapeutics (Chord) step into a new partnership to develop CRD1 for treatment of orphan autoimmune diseases.CDR1 is a new formulation of cladribine, an immunosuppressant with...

weiter zu "AOP Orphan Pharmaceuticals AG and Chord Therapeutics Announce a Partnership to Develop CRD1 (Cladribine) for Treatment of Orphan Autoimmune Diseases"

AOP Orphan´s EMA marketing authorization application for Ropeginterferon alfa-2b/BESREMi® resulted in a positive opinion adopted by EMA´s CHMP. The European Commission will review the CHMP recommendation and usually delivers its...

weiter zu "AOP Orphan announces positive CHMP opinion for Ropeginterferon alfa-2b/BESREMi®"

High rates of durable hematological response and symptom control with good tolerability were reconfirmed with Ropeginterferon alfa-2b after 36 months of treatment. Disease Modification by Ropeginterferon alfa-2b was...

weiter zu "AOP Orphan announces three-year results on Ropeginterferon alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2018"

Study protocol "Landiolol in patients with septic shock resident in an intensive care unit (LANDISEP): study protocol for a randomized controlled trial" Download the LANDI-SEP Trials 2018 here

weiter zu "LANDI-SEP Trials 2018"

On November 13th AOP Orphan was awarded with the MERCUR prize for Innovation in Life Science by the Chamber of Commerce in Vienna, Austria. We feel very proud to receive this recognition and want to thank all colleagues, partners...

weiter zu "AOP Orphan is the winner of the MERCUR Innovation Award in the category Life Science for the clinical development project “Ropeginterferon α-2b”"

Abstract Polycythemia vera is characterized by the acquisition of the JAK2V617F mutation. Recommended treatments include hydroxyurea and interferon-alpha. Several groups have reported a reduction in the JAK2 mutant allele burden...

weiter zu "Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo"

AOP Orphan´s submission for marketing authorization of Ropeginterferon alfa-2b for treatment of Polycythemia Vera (PV) in the European Union (EU) has resumed after clock-stop. The conclusion of this centralized procedure is...

weiter zu "AOP Orphan announces progress of its European Marketing Authorization Procedure of Ropeginterferon alfa-2b"

Since its foundation in 1996 AOP Orphan Pharmaceuticals AG has successfully grown from a single person organization to a fully integrated worldwide acting orphan pharmaceutical company with more than 200 employees. To prepare for...

weiter zu "AOP Orphan Chief Executive Officer & Executive Board of Directors Change"

AOP Orphan Pharmaceuticals AG, the Austrian specialist for rare diseases, will implement ‘Mobile IntelligenceTM (MI)’ - the smart CRM Tool from leading Life-Sciences consultant, IQVIA.

weiter zu "AOP Orphan to implement innovative CRM system in collaboration with IQVIA Austria "

Bioprojet Pharma SAS and AOP Orphan Pharmaceuticals AG (AOP Orphan) entered a distribution agreement for Wakix®The covered territory includes mainly Central and Northern European countriesWakix® is approved for treatment of...

weiter zu "AOP Orphan will distribute Wakix® (pitolisant) from Bioprojet Pharma SAS in Austria, Nordic countries and Central Eastern Europe"

AOP Orphan supports the Christian Doppler Laboratory for Iron Metabolism and Anemia Research at the Medical University of Innsbruck, Austria, opening on January 31st, 2018. To read the full press release in German, please click...

weiter zu "The Medical University of Innsbruck: Christian Doppler Laboratory for Iron Metabolism and Anemia Research is opened."

High rates and durable Clinical and Hematological response were achieved with Ropeginterferon alfa-2b at 24 months of treatment  The disease modifying capability of Ropeginterferon alfa-2b was further supported by 24 month...

weiter zu "AOP Orphan announces two-year results on Ropeginterferon alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2017"

PDF to download 

weiter zu "AOP In Press: UK CPA in Practice"

AOP Orphan Pharmaceuticals AG announced today that it has acquired Selisistat, a highly selective SIRT1 inhibitor, which in experimental studies has previously shown potential disease modifying properties in a number of...

weiter zu "AOP Orphan Pharmaceuticals AG to acquire Selisistat a clinical stage drug candidate for the treatment of Huntington’s disease (HD)"

An interview with Dr Rudolf Widmann, CEO and Dr Christoph Klade, CSO about the current status of Vienna, Austria as a Research & Development base, its specifics, hurdles and chances,  which was published recently in...

weiter zu "Austria as a Research & Development base"

Cancer Drug News 733

weiter zu "AOP in Press: "New Therapies To Struggle Against Established Hematology""

Long-term maintenance treatment of Polycythemia Vera (PV) patients with Ropeginterferon alfa-2b administered every 4 weeks is feasible, efficacious and well toleratedHome self-administration of individual doses with a pen is well...

weiter zu "AOP and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera"

AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that RAPIBLOC® (Rapibloc, 300 mg powder for solution for infusion) will as of June 19th be first commercialized by its distribution partner Amomed Pharma GmbH (Amomed)...

weiter zu "AOP Orphan Pharmaceuticals AG and Amomed Pharma GmbH announce the launch of RAPIBLOC® (Landiolol) in Germany and Austria."

An interview with Dr Rudolf Widmann, CEO and Dr Christoph Klade, CSO about AOP Orphan’s commitment to sustainable innovation for the benefit of patients with rare diseases and Austria as a research location was published recently...

weiter zu "Rare Diseases: AOP Orphan Pharmaceuticals AG invests in sustainable Research & Development"

The internationally active, Vienna-based pharmaceutical company AOP Orphan, which specializes in rare diseases, has appointed Miroslaw Jan Lubecki MD, MBA to join the management team as Chief of Commercial Operations.

weiter zu "Miroslaw Jan Lubecki – newly appointed Chief of Commercial Operations "

EMA started the centralized marketing authorization procedure for Ropeginterferon alfa-2b for treatment of Polycythemia Vera (PV) on Feb 23rd 2017.
Ropeginterferon alfa-2b is a novel mono-pegylated interferon with an improved...

weiter zu "AOP Orphan Pharmaceuticals AG announces start of EMA marketing authorization application procedure for Ropeginterferon alfa-2b in Polycythemia Vera"

At 12 months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) PROUD-PV demonstrated a significantly better safety and tolerability profile of ropeginterferon...

weiter zu "AOP Orphan and PharmaEssentia announce pivotal phase III results for ropeginterferon alfa-2b in Polycythemia Vera"

Highlights: Ultra-short acting and highly cardio-selective beta blocker Rapibloc® (Landiolol) receives regulatory approval in Europe.Rapibloc® (Landiolol) allows rapid control of heart rate with a straightforward dosing scheme...

weiter zu "AOP Orphan Pharmaceuticals AG announces European “approvable” opinion of its ultra-short acting beta blocker Rapibloc® (Landiolol)"

Dr Roland Bindeus (38) took control of the Hematology & Oncology Business Unit at the Austrian pioneer of rare diseases, AOP Orphan, at the beginning of April. The biochemist was most recently the general manager of Baxalta...

weiter zu "Roland Bindeus moves from Baxalta to AOP Orphan – new Head of the Hematology & Oncology Business Unit"

The internationally active, Vienna-based pharmaceutical company AOP Orphan, which specialises in rare diseases, has appointed Suzie McFadzean to join the management team as Chief of Commercial Operations. British-born Suzie...

weiter zu "Suzie McFadzean – new Chief of Commercial Operations "

AOP Orphan Pharmaceuticals AG announced today the regulatory submission of Tetrabenazine for the treatment of tardive dyskinesia in a DCP (decentralized procedure) for several European countries with UK being reference member...

weiter zu "AOP Orphan strengthens core CNS specialty business with high promise in movement disorder treatments "

As an easy-to-use and highly reliable inhalation powder, the antipsychotic ADASUVE® has revolutionized the treatment of agitation in patients suffering from schizophrenia or bipolar disorder. This was also confirmed by experts...

weiter zu "Innovative antipsychotic ADASUVE® to benefit even more patients"

The Austrian pharmaceutical pioneer AOP Orphan is now bringing Lojuxta® (lomitapide) Capsules to the Austrian market

weiter zu "Homozygous Familial Hypercholesterolaemia"

Today AOP Orphan Pharmaceuticals AG, Austria, and Rigi Healthcare AG, Switzerland, announced the creation of Rigi Orphan Inc, USA.  The new company will focus on the development, in-licensing and commercialization of...

weiter zu "AOP Orphan and Rigi Healthcare start Rigi Orphan Inc., USA "

INDIANAPOLIS, IN — CONFLUENCE PHARMACEUTICALS and AOP Orphan Pharmaceuticals AG (“AOP”), announced today they have signed a definitive agreement to co-develop and market Confluence’s lead asset, a product for the treatment of...

weiter zu "Confluence Pharmaceuticals Signs Co-Development and Marketing Agreement with AOP Orphan for Fragile X Syndrome Drug"

Highlights: AOP Orphan announces completion of recruitment of its pivotal phase III trial PROUD-PV (www.proud-pv.com) to support global licensure of Ropeginterferon alfa 2b - Ropeginterferon alfa 2b is a novel, long-acting,...

weiter zu "AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV applying Ropeginterferon alfa 2b, a novel, long-acting, mono-pegylated Interferon for treatment of Polycythemia Vera"

The Austrian pharmaceutical company AOP Orphan, which specialises in rare diseases and innovative therapies, will in future market the two special preparations by the highly innovative, publicly listed company Cardiome Pharma...

weiter zu "AOP Orphan to be commercialization partner for Canadian pharmaceutical specialist Cardiome "

The pharmaceutical company AOP Orphan, a European pioneer in the field of rare diseases, is expanding its sales area for the special preparation Thromboreductin® to include the large Russian market. This means that the drug,...

weiter zu "AOP Orphan brings Thromboreductin® to the Russian market"

The Austrian pharmaceutical company AOP Orphan, which specialises in rare diseases and innovative therapies, will in future market the antiarrhythmic drug BRINAVESS®, developed by Cardiome Pharma Corp., Canada, in Central Europe....

weiter zu "AOP Orphan to market the innovative antiarrhythmic drug BRINAVESS® exclusively in Central Europe"

The Austrian pharmaceutical company AOP Orphan is a European pioneer in the field of rare diseases. Industry expert Hans Peter Hasler (58) joined AOP Orphan’s Supervisory Board at the beginning of the year. The Swiss native...

weiter zu "Internationally renowned pharmaceutical expert Hans Peter Hasler strengthens AOP Orphan Supervisory Board"

AOP Orphan and Ferrer Internacional are expanding their long-standing partnership to include the marketing of the anti-psychotic drug Adasuve® (Staccato® Loxapine) in Central and Eastern Europe.

weiter zu "Partnership between AOP Orphan and Ferrer: Joint marketing of Adasuve® in CEE"

In order to add impetus to the rapid expansion of recent years, the Austrian pharmaceutical company AOP Orphan is strengthening its management team.

weiter zu "AOP Orphan Expands and Enlarges the Management Team"

AOP Orphan announces progress of pan-European phase III trial PROUD-PV to support European Marketing Authorization of AOP2014/P1101, a next-generation, mono-pegylated Interferon alpha 2b.

weiter zu "AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV of novel mono-pegylated Interferon alpha 2b for the treatment of Polycythemia vera"

AOP Orphan Pharmaceuticals has been awarded the exclusive distributions rights for Brinavess® (vernakalant) by Cardiome Pharma Corporation for most Central and Eastern European countries, as well as for Switzerland and Austria....

weiter zu "AOP Orphan expands its range of special cardiovascular preparations"

The Austrian pharmaceutical company AOP Orphan – a European pioneer in the field of rare diseases – has brought on board a health sector expert, Andreas Steiner (53), with many years of management experience to become CFO.

weiter zu "Andreas Steiner – New CFO at AOP Orphan"

Non-inferiority of anagrelide compared to hydroxyurea in WHO-essential ET. (Prepublished online, Blood, Jan. 11, 2013)

weiter zu "Essential Thrombocythemia (ET) – Convincing data of ANAHYDRET study now published "

AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that based on promising phase II data it will initiate a phase III trial to support European Marketing Authorization of a novel mono-pegylated Interferon alpha 2b...

weiter zu "AOP Orphan Pharmaceuticals reports positive phase II data of novel mono-pegylated Interferon alpha 2b for treatment of Polycythemia Vera (PV) "

A documentary on living with rare diseases; by Edith Bachkönig (currently available in German only)

weiter zu "Video "Loser in the gene roulette" "

At AOP Orphan are European pioneers in the field of Orphan Diseases. We research, develop, produce, and distribute innovative solutions for Rare Diseases worldwide.

weiter zu "AOP Orphan - A European Pioneer in the field of Rare Diseases"

With the arrival of Dr. Christoph Klade (43), we are pleased to welcome a renowned expert to our management team. He will be in charge of research and development activities sector here at AOP Orphan. AOP Orphan is an Austrian...

weiter zu "Meet Dr. Christoph Klade, the newest member of the Rare Disease specialist AOP Orphan’s management team"